Phaseline

Targets › UGCG

UGCG (Ceramide glucosyltransferase): drug programs, companies and trials

4 programs from 4 companies in 11 trials: 10 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2027.

Participates in the initial step of the glucosylceramide-based glycosphingolipid/GSL synthetic pathway at the cytosolic surface of the Golgi. Catalyzes the transfer of glucose from UDP-glucose to ceramide to produce glucosylceramide/GlcCer (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine). (UniProt, Q16739)

Open in Phaseline: the race on UGCG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiVenglustat (GZ402671)
Ceramide glucosyltransferase inhibitor
UGCGPhase 3Gaucher's Disease Type III; Fabry DiseaseJan 2027
Amicus TherapeuticsMiglustat (AT2221)
Ceramide glucosyltransferase inhibitor
UGCGPhase 3Pompe Disease (Late-onset); Glycogen Storage Disease Type II Infantile OnsetMar 2027
AzafarosNizubaglustat (AZ-3102)
Glucosidase inhibitor
GBA, UGCGPhase 3Gangliosidoses, GM2; Niemann-Pick Type C Disease; GM2 GangliosidosisJun 2027
Idorsia PharmaceuticalsLucerastat
Ceramide glucosyltransferase inhibitor
UGCGPhase 3Fabry DiseaseFeb 2029

Conditions

Fabry Disease (4) Niemann-Pick Type C Disease (2) Pompe Disease (Late-onset) (1) Glycogen Storage Disease Type II Infantile Onset (1) Gaucher's Disease Type III (1) Gangliosidoses, GM2 (1) GM2 Gangliosidosis (1)

Modalities

small molecule (3), mixed (1)

Companies

Amicus Therapeutics (1) Sanofi (1) Azafaros (1) Idorsia Pharmaceuticals (1)

Related targets

GBA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.